Utilization of GP IIb/IIIa inhibitors in peripheral percutaneous interventions: Current applications and in-hospital outcomes at a tertiary referral center

Journal of Invasive Cardiology

Volumn 20, Issue 6, 2008, Pages 266-269

  Shammas, Nicolas W ^a   Dippel, Eric J ^a   Shammas, Gail A ^a   Kumar, Alisha ^a   Jerin, Michael ^a   Kennedy, Lynn ^a  

^a MIDWEST CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

Author keywords

Antiplatelets; GP IIb IIIa inhibitors; Peripheral angioplasty; Thrombus

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST;

AGED; AMPUTATION; ANGIOCARDIOGRAPHY; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CLINICAL ARTICLE; COMORBIDITY; DEATH; DEMOGRAPHY; DRUG USE; FEMALE; HEART INFARCTION; HUMAN; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PROGNOSIS; THROMBOCYTOPENIA; THROMBUS;

AGED; ANGIOPLASTY, BALLOON; ANTIBODIES, MONOCLONAL; CORONARY THROMBOSIS; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INPATIENTS; MALE; MYOCARDIAL INFARCTION; PEPTIDES; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; THROMBOLYTIC THERAPY; TREATMENT OUTCOME;

EID: 46349094804     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Shammas NW, Dippel EJ, Gayton L, et al. Prevalence of thrombus in patients with a recent history of claudication or rest limb pain: An intravascular ultrasound assessment. Presented at New Cardiovascular Horizons, New Orleans, September 5-7, 2007.
2. Duda SH, Tepe G, Luz O, et al. Peripheral artery occlusion: Treatment with abciximab plus urokinase versus with urokinase alone - A randomized pilot trial (the PROMPT Study). Platelet receptor antibodies in order to manage peripheral artery thrombosis. Radiology 2001;221:689-696.
3. Ouriel K, Castaneda F, McNamara T, et al. Reteplase monotherapy and reteplase/abciximab combination therapy in peripheral arterial occlusive disease: Results from the RELAX trial. J Vasc Interv Radiol 2004;15:229-238.
4. Rocha-Singh KJ, Rutherford J. Glycoprotein IIb-IIIa receptor inhibition with eptifibatide in percutaneous intervention for symptomatic peripheral vascular disease: The Circulate pilot trial. Catheter Cardiovasc Interv 2005;66:470-473.
5. Allie DE, Hebert CJ, Lirtzman MD, et al. A safety and feasibility report of combined direct thrombin and GP IIb/IIIa inhibition with bivalirudin and tirofiban in peripheral vascular disease intervention: Treating critical limb ischemia like acute coronary syndrome. J Invasive Cardiol 2005;17:427-432.
6. Allie DE, Hebert CJ, Lirtzman MD, et al. Combined glycoprotein IIb/IIIa and direct thrombin inhibition with eptifibatide and bivalirudin in the interventional treatment of critical limb ischemia: A safety and feasibility report. Vascular Disease Management 2006;3:368-375.
7. Shammas NW, Lemke JH, Dippel EJ, et al. In-hospital complications of peripheral vascular interventions using unfractionated heparin as the primary anticoagulant. J Invasive Cardiol 2003;15:242-246.
8. Gibson CM, Kirtane AJ, Murphy SA, et al; TIMI Study Group. Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial. Am Heart J 2006;152:668-675.
9. Zeymer U, Wienbergen H. A review of clinical trials with eptifibatide in cardiology. Cardiovasc Drug Rev 2007;25:301-315.
10. Islam MA, Blankenship JC, Balog C, et al; EPISTENT Investigators. Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT). Am J Cardiol 2002;90:916-921.
11. Topol EJ, Lincoff AM, Kereiakes DJ, et al. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am J Med 2002;113:1-6.
12. Chen SM, Hsieh YK, Guo GB, et al. Angiographic and clinical outcome in ST-segment elevation myocardial infarction patients receiving an adjunctive double bolus regimen of tirofiban for primary percutaneous coronary intervention. Circ J 2006;70:536-541.
13. Ansel GM, Silver MJ, Botti CF Jr, et al. Functional and clinical outcomes of nitinol stenting with and without abciximab for complex superficial femoral artery disease: A randomized trial. Catheter Cardiovasc Interv 2006;67:288-297.
14. Shammas NW, Dippel EJ. Evidence-based management of peripheral vascular disease. Curr Atheroscler Rep 2005;7:358-363.
15. Rossi E, Biasucci LM, Citterio F, et al. Risk of myocardial infarction and angina in patients with severe peripheral vascular disease: Predictive role of C-reactive protein. Circulation 2002;105:800-803.
16. Laird JR, Zeller T, Gray BH, et al; LACI Investigators. Limb salvage following laser-assisted angioplasty for critical limb ischemia: Results of the LACI multicenter trial. J Endovasc Ther 2006;13:1-11.
17. Shammas NW, Dippel EJ, Lemke JH, et al. Eptifibatide does not reduce inflammatory markers in patients undergoing peripheral vascular interventions: Results of the INFLAME trial. J Invasive Cardiol 2006;18:6-12.
18. Shlansky-Goldberg R. Platelet aggregation inhibitors for use in peripheral vascular interventions: What can we learn from the experience in the coronary arteries? J Vasc Interv Radiol 2002;13:229-246.